# US 2016/0355560 A1 · Netrin-1 and dependence receptor proteins and methods of use

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0355560 A1
- Document ID: US20160355560A1
- Status: Published application
- Kind: A1
- Application number: 15/117,863
- Filed: 2015-02-10
- Published: 2016-12-08
- Earliest claimed: 2014-02-10
- Assignees: University of Manitoba
- Applicants: University of Manitoba
- Inventors: Jorg Stetefeld
- Web page: https://patentgrep.com/patent/US20160355560A1

## CPC

- C07K 14/475: Growth factors; Growth regulators
- A61K 39/395: Antibodies (agglutinins A61K38/36 {; as drug carriers A61K47/50}); Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61P 35/00: Antineoplastic agents
- C07K 14/47: from mammals
- C07K 14/70503: {Immunoglobulin superfamily}
- C07K 16/18: against material from animals or humans
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K 2317/34: Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C07K 2319/00: Fusion polypeptide
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Provided herein are fragments of Netrin-1 proteins, fragments of DCC proteins and NEO1 proteins, and antibodies to epitopes located within the fragments of Netrin-1, DCC, and/or NEO1. Also provided herein are methods for using the fragments and antibodies, including methods for inhibiting binding of Netrin-1 to an UNC5 protein, a DCC protein, and/or a NEO1 protein. Other methods provided herein include inducing apoptosis of a cell, and reducing formation of multimers of Netrin-1 proteins, and treating a subject having a cancer or at risk of having a cancer.

## Claims

### Claim 1

A NET1 fragment comprising an amino acid sequence having at least 80% identity to amino acids CNLHARRCRFNMELYKLSGRKSGGVCLN (SEQ ID NO:16),
wherein the NET1 fragment comprises an UNC5 binding domain HARRCR, wherein the UNC5 binding domain comprises conservative substitutions in HARRCR at positions 1, 2, 3, 4, 5, 6, or a combination thereof,
wherein the NET1 fragment comprises a DCC/NEO1 binding domain MELYKLS, wherein the DCC/NEO1 binding domain comprises conservative substitutions in MELYKLS at positions 1, 2, 3, 4, 5, 6, 7, or a combination thereof, and
wherein the NET1 fragment comprises UNC5 binding activity and DCC/NEO1 binding activity.

### Claim 2

A DCC/NEO1 fragment comprising an amino acid sequence having at least 80% identity to amino acids MMPPVGVQASILSHDTIRITWADNSLPKHQKITDSRYYTVRWKTNIPANTKYKNANATT LSYLVTGLKPNTLYEFSVMVTKGRRSSTWSMTAHGATFELVP (SEQ ID NO:18) or MLPPVGVQAVALTHEAVRVSWADNSVPKNQKTSDVRLYTVRWRTSFSASAKYKSEDT TSLSYTATGLKPNTMYEFSVMVTKNRRSSTWSMTAHATTYEAAP (SEQ ID NO:19),
wherein the DCC/NEO1 fragment comprises a NET1 binding domain MVTK(N/G)RRSSTWS, wherein the NET1 binding domain comprises conservative substitutions in MVTK(N/G)RRSSTWS at positions 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, or a combination thereof,
wherein the DCC/NEO1 fragment comprises NET1 binding activity.

### Claim 3 (depends on 1)

The NET1 fragment of claim 1 wherein the fragment is a fusion protein comprising a heterologous amino acid sequence.

### Claim 4 (depends on 2)

The DCC/NEO1 fragment of claim 2 wherein the fragment is a fusion protein comprising a heterologous amino acid sequence.

### Claim 5 (depends on 1)

A composition comprising the NET1 fragment of claim 1 and a pharmaceutically acceptable carrier.

### Claim 6 (depends on 2)

A composition comprising the DCC/NEO1 fragment of claim 2 and a pharmaceutically acceptable carrier.

### Claim 7 (depends on 1)

A method for inhibiting binding of a NET1 protein to an UNC5 protein comprising contacting an UNC5 protein with the NET1 fragment of claim 1.

### Claim 8 (depends on 1)

A method for inhibiting binding of a NET1 protein to a DCC/NEO1 protein comprising contacting a DCC protein with the NET1 fragment of claim 1.

### Claim 9 (depends on 2)

A method for inhibiting binding of a DCC or a NEO1 protein to a NET1 protein comprising contacting a NET1 protein with the DCC/NEO1 fragment of claim 2.

### Claim 10 (depends on 7)

The method of claim 7 wherein the contacting is performed in vitro.

### Claim 11 (depends on 7)

The method of claim 7 wherein the contacting is performed in vivo.

### Claim 12

An antibody that specifically binds an epitope located within an amino acid sequence HARRCR or MELYKLS.

### Claim 13

An antibody that specifically binds an epitope located within an amino acid sequence MVTK(N/G)RRSSTWS.

### Claim 14

An antibody that specifically binds to an epitope located within an amino acid sequence of a V-2 fragment CNLHARRCRFNMELYKLSGRKSGGVCLN (SEQ ID NO:16).

### Claim 15

An antibody that specifically binds to an epitope located within an amino acid sequence of a the V-2 region CNCNLHARRCRFNMELYKLSGRKSGGVCLNCRHNTAGRHCHYCKEGXYRDMGKPITH RKACKAC (SEQ ID NO: 17), where the amino acid X is F or Y.

### Claim 16 (depends on 12)

The antibody of claim 12 wherein the antibody is a monoclonal antibody.

### Claim 17 (depends on 12)

The antibody of claim 12 wherein the antibody is a polyclonal antibody.

### Claim 18

(canceled)

### Claim 19 (depends on 1)

A method for inducing apoptosis of a cell comprising:
contacting a cell with
i) the NET1 fragment of claim 1 or ii) an antibody that specifically binds an epitope located within an amino acid sequence HARRCR or MELYKLS,
wherein the cell is a cell that expresses a DCC protein, a NEO1 protein, an UNC5 protein, or a combination thereof, on the surface of the cell.

### Claim 20 (depends on 2)

A method for inducing apoptosis of a cell comprising:
contacting a cell with i) the DCC/NEO1 fragment of claim 2 or ii) an antibody that specifically binds an epitope located within an amino acid sequence MVTK(N/G)RRSSTWS,
wherein the cell is a cell that expresses a DCC protein, a NEO1 protein, or a combination thereof, on the surface of the cell.

### Claim 21 (depends on 19)

The method of claim 19 wherein the cell is ex vivo.

### Claim 22 (depends on 19)

The method of claim 19 wherein the cell is in vivo.

### Claim at position 23

-28. (canceled)

### Claim 29

A NET1 fragment that comprises an alteration of an amino acid corresponding to L359, E385, T415, 1452, or a combination thereof, of a NET1 protein, wherein the NET1 fragment will not form a multimer.

### Claim 30 (depends on 29)

A method comprising contacting a cell with the NET1 fragment of claim 29.

### Claim 31 (depends on 30)

The method of claim 30 wherein the cell is ex vivo.

### Claim 32 (depends on 30)

The method of claim 30 wherein the cell is in vivo.

### Claim 33 (depends on 30)

The method of claim 30 wherein the cell is a cancer cell.

### Claim 34 (depends on 31)

The method of claim 31 wherein the cancer cell is selected from colonic carcinoma cell, breast cancer cell, prostate cancer cell, adenocarcinoma cancer cell, neuroblastoma cancer cell, and lung cancer cell.

### Claim at position 30

-38. (canceled)
